Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a ...

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition. | After ...

Analysts at William Blair lifted their Q2 2026 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, April 1st. William Blair analyst L.

Apellis Pharmaceuticals, Inc.’s APLS share price has dipped by 11.32%, which has investors questioning if this is right time to buy.

The difference between biotech and pharma is that biotech companies make medicines from living organisms called biologics, while pharma (pharmaceutical) companies develop drugs from chemicals.

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Apellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Empaveli (pegcetacoplan) for two rare and severe kidney ...

Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of priority review status to Empaveli (pegcetacoplan) to treat the rare and ...

Apellis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted... ByInvesting.com • 11 hours ago Apellis Pharma stock hits 52 ...